Dr. Chumpitazi is a board certified pediatric gastroenterologist and tenure track Assistant Professor at Baylor College of Medicine (BCM) with a strong background in clinical research methods and an established commitment to apply these skills to the study of irritable bowel syndrome (IBS). His long term career goal is to become an independent NIH-funded physician scientist proficient in patient oriented research to elucidate the underlying pathobiology in childhood IBS and develop novel and easily applied therapies. His focus is on understanding the interactions between diet and the gut microbiome that induce GI symptoms in childhood IBS. The objective of the current K23 proposal is to obtain training in acquiring, analyzing, and translating data from metagenomic- and metabolomic-based studies related to the gut microbiota to help achieve his long term goal. His short term goals in this proposal are to: 1) Acquire expertise in the study of diet-microbiota interactions by learning methods used to determine microbial community composition, microbial biochemical pathway potential, and microbial metabolite characterization;and 2) Establish an area of independent research by generating a critical mass of data and publications to support a successful R01 NIH grant application. Dr. Chumpitazi's research proposal's objective is to understand the role of the gut microbiome in diet- induced GI symptoms in children with IBS by performing a randomized, double blind, placebo controlled dietary fructan challenge. His hypothesis is that generation of GI symptoms in children with IBS after fructan ingestion is related to gut microbial community composition, its potential for fructan metabolism, and the fermentation products resulting from fructan metabolism.
In Aim 1, microbial community composition will be characterized and compared between fructan sensitive (Fsens) and fructan insensitive (Fins) children.
In Aim 2, microbial metagenomic signatures related to fructan metabolism will be compared between Fsens and Fins children.
Aim 3 will identify potential relationships between products of fructan metabolism and IBS symptoms.
These aims support the candidate's career development by providing training in mechanistic aspects of IBS pathobiology as related to diet and gut microbiota/metagenomic/metabolomic interactions. Additional key elements of the candidate's training plan include: 1) A mentorship and advisory team, which includes internationally recognized, independently funded investigators with expertise in childhood functional GI disorders, bioinformatics, metagenomics, and metabolomics;2) Advanced coursework in computational biology, microbiology, sequence analysis, and statistical modeling;and 3) Scholarly activities designed to foster independence. Finally, the candidate's research environment is a preeminent academic research institution (Baylor College of Medicine) closely allied with the NIH funded (DK58338) Texas Medical Center Digestive Disease Center which will support the proposed studies and career development plan. This environment will provide a productive and collaborative atmosphere to accomplish the research and training goals. With these ample resources, Dr. Chumpitazi will complete his proposed career development plan and research project in a timely manner and set the stage for his progression to an independently funded physician scientist in patient oriented research.
Irritable bowel syndrome (IBS) is an often debilitating functional gastrointestinal disorder that affects 15-20% of school aged children and millions of adults in the United States and leads to significant impairment in quality of life, missed school and work, and substantial health care costs (approximately 30 billion dollars per year for adults alone). The goal of this proposal and our long term goals are to understand how food interacts with the bacteria of the gut to produce IBS symptoms. Results from these studies likely will lead to better IBS treatments and enhance our overall understanding of the critical role the gut bacteria play in health and disease.
|Chumpitazi, Corrie E; Henkel, Erin B; Valdez, Karina L et al. (2016) Soap Suds Enemas Are Efficacious and Safe for Treating Fecal Impaction in Children With Abdominal Pain. J Pediatr Gastroenterol Nutr 63:15-8|
|Chumpitazi, Bruno P; Weidler, Erica M; Shulman, Robert J (2016) Lactulose Breath Test Gas Production in Childhood IBS is Associated with Intestinal Transit and Bowel Movement Frequency. J Pediatr Gastroenterol Nutr :|
|Chumpitazi, B P; Self, M M; Czyzewski, D I et al. (2016) Bristol Stool Form Scale reliability and agreement decreases when determining Rome III stool form designations. Neurogastroenterol Motil 28:443-8|
|Chumpitazi, Bruno P; Weidler, Erica M; Lu, Diana Y et al. (2016) Self-Perceived Food Intolerances Are Common and Associated with Clinical Severity in Childhood Irritable Bowel Syndrome. J Acad Nutr Diet 116:1458-64|
|Chumpitazi, Bruno P; Shulman, Robert J (2016) Dietary Carbohydrates and Childhood Functional Abdominal Pain. Ann Nutr Metab 68 Suppl 1:8-17|
|Wong, G K; Shulman, R J; Chumpitazi, B P (2015) Gastric emptying scintigraphy results in children are affected by age, anthropometric factors, and study duration. Neurogastroenterol Motil 27:356-62|
|Chumpitazi, B P; Shulman, R J (2015) Editorial: predicting response to a low FODMAP diet in children--authors' reply. Aliment Pharmacol Ther 42:776|
|Chumpitazi, B P; Shulman, R J (2015) Letter: avoid FODMAPs or follow simple tips--authors' reply. Aliment Pharmacol Ther 42:1330|
|Kearns, Gregory L; Chumpitazi, Bruno Pedro; Abdel-Rahman, Susan M et al. (2015) Systemic exposure to menthol following administration of peppermint oil to paediatric patients. BMJ Open 5:e008375|
|Chumpitazi, B P; Cope, J L; Hollister, E B et al. (2015) Randomised clinical trial: gut microbiome biomarkers are associated with clinical response to a low FODMAP diet in children with the irritable bowel syndrome. Aliment Pharmacol Ther 42:418-27|
Showing the most recent 10 out of 12 publications